Cargando…
Transcriptomic profiling revealed FZD10 as a novel biomarker for nasopharyngeal carcinoma recurrence
BACKGROUND: Nasopharyngeal carcinoma (NPC) is a type of cancers that develops in the nasopharynx, the very upper part of the throat behind the nose. NPC is typically diagnosed in later stages of the disease and has a high rate of recurrence due to the location of the tumor growth site. In this study...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909960/ https://www.ncbi.nlm.nih.gov/pubmed/36776376 http://dx.doi.org/10.3389/fonc.2022.1084713 |
_version_ | 1784884685994721280 |
---|---|
author | Tulalamba, Warut Ngernsombat, Chawalit Larbcharoensub, Noppadol Janvilisri, Tavan |
author_facet | Tulalamba, Warut Ngernsombat, Chawalit Larbcharoensub, Noppadol Janvilisri, Tavan |
author_sort | Tulalamba, Warut |
collection | PubMed |
description | BACKGROUND: Nasopharyngeal carcinoma (NPC) is a type of cancers that develops in the nasopharynx, the very upper part of the throat behind the nose. NPC is typically diagnosed in later stages of the disease and has a high rate of recurrence due to the location of the tumor growth site. In this study, we compared the gene expression profiles of NPC tissues from patients with and without recurrence to identify potential molecular biomarkers of NPC recurrence. METHODS: Microarrays were used to analyze the expression of genes in 15 NPC tissues taken at the time of diagnosis and at the site of recurrence following therapeutic treatment. Pathway enrichment analysis was used to examine the biological interactions between the major differentially expressed genes. The target identified was then validated using immunohistochemistry on 86 NPC tissue samples. RESULTS: Our data showed that the Wnt signaling pathway was enhanced in NPC tissues with recurrence. FZD10, a component of the Wnt signaling pathway, was significantly expressed in NPC tissues, and was significantly associated with NPC recurrence. CONCLUSION: Our study provides new insights into the pathogenesis of NPC and identifies FZD10 as a potential molecular biomarker for NPC recurrence. FZD10 may be a promising candidate for NPC recurrence and a potential therapeutic target. |
format | Online Article Text |
id | pubmed-9909960 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99099602023-02-10 Transcriptomic profiling revealed FZD10 as a novel biomarker for nasopharyngeal carcinoma recurrence Tulalamba, Warut Ngernsombat, Chawalit Larbcharoensub, Noppadol Janvilisri, Tavan Front Oncol Oncology BACKGROUND: Nasopharyngeal carcinoma (NPC) is a type of cancers that develops in the nasopharynx, the very upper part of the throat behind the nose. NPC is typically diagnosed in later stages of the disease and has a high rate of recurrence due to the location of the tumor growth site. In this study, we compared the gene expression profiles of NPC tissues from patients with and without recurrence to identify potential molecular biomarkers of NPC recurrence. METHODS: Microarrays were used to analyze the expression of genes in 15 NPC tissues taken at the time of diagnosis and at the site of recurrence following therapeutic treatment. Pathway enrichment analysis was used to examine the biological interactions between the major differentially expressed genes. The target identified was then validated using immunohistochemistry on 86 NPC tissue samples. RESULTS: Our data showed that the Wnt signaling pathway was enhanced in NPC tissues with recurrence. FZD10, a component of the Wnt signaling pathway, was significantly expressed in NPC tissues, and was significantly associated with NPC recurrence. CONCLUSION: Our study provides new insights into the pathogenesis of NPC and identifies FZD10 as a potential molecular biomarker for NPC recurrence. FZD10 may be a promising candidate for NPC recurrence and a potential therapeutic target. Frontiers Media S.A. 2023-01-20 /pmc/articles/PMC9909960/ /pubmed/36776376 http://dx.doi.org/10.3389/fonc.2022.1084713 Text en Copyright © 2023 Tulalamba, Ngernsombat, Larbcharoensub and Janvilisri https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Tulalamba, Warut Ngernsombat, Chawalit Larbcharoensub, Noppadol Janvilisri, Tavan Transcriptomic profiling revealed FZD10 as a novel biomarker for nasopharyngeal carcinoma recurrence |
title | Transcriptomic profiling revealed FZD10 as a novel biomarker for nasopharyngeal carcinoma recurrence |
title_full | Transcriptomic profiling revealed FZD10 as a novel biomarker for nasopharyngeal carcinoma recurrence |
title_fullStr | Transcriptomic profiling revealed FZD10 as a novel biomarker for nasopharyngeal carcinoma recurrence |
title_full_unstemmed | Transcriptomic profiling revealed FZD10 as a novel biomarker for nasopharyngeal carcinoma recurrence |
title_short | Transcriptomic profiling revealed FZD10 as a novel biomarker for nasopharyngeal carcinoma recurrence |
title_sort | transcriptomic profiling revealed fzd10 as a novel biomarker for nasopharyngeal carcinoma recurrence |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909960/ https://www.ncbi.nlm.nih.gov/pubmed/36776376 http://dx.doi.org/10.3389/fonc.2022.1084713 |
work_keys_str_mv | AT tulalambawarut transcriptomicprofilingrevealedfzd10asanovelbiomarkerfornasopharyngealcarcinomarecurrence AT ngernsombatchawalit transcriptomicprofilingrevealedfzd10asanovelbiomarkerfornasopharyngealcarcinomarecurrence AT larbcharoensubnoppadol transcriptomicprofilingrevealedfzd10asanovelbiomarkerfornasopharyngealcarcinomarecurrence AT janvilisritavan transcriptomicprofilingrevealedfzd10asanovelbiomarkerfornasopharyngealcarcinomarecurrence |